Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study

Anna Viola, Daniela Pugliese, Sara Renna, Federica Furfaro, Flavio Caprioli, Renata D'Incà, Fabrizio Bossa, Stefano Mazza, Giuseppe Costantino, Massimo Claudio Fantini, Gionata Fiorino, Angela Alibrandi, Ambrogio Orlando, Alessandro Armuzzi, Walter Fries

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Anti-TNF therapies infliximab (IFX), adalimumab (ADA), and golimumab (GOL) are approved for treating moderate to severe ulcerative colitis (UC). In UC, only the switch from IFX to ADA has been investigated, reaching no more than 10-43% remission rates at 12 months.AIM: Of the present study was to investigate disease outcome after a switch from subcutaneous (SC) agents to the intravenous (IV) agent (IFX).METHODS: In this retrospective multicentre study, we analysed the charts of UC patients unresponsive/intolerant or with secondary loss of response (LOR) to ADA or GOL who were switched to IFX. We evaluated clinical response and remission together with adverse events at 3, 6, and 12 months follow-up.RESULTS: Seventy-six patients were included; 38 patients started ADA and 38 started GOL for a mean therapy duration of 6 ± 6 months. Indications for switch were adverse events in 3%, primary failure in 79%, and LOR in 18% of patients. Clinical remission was reached by 47%, 50%, and 77% of patients, respectively. Patients that switched for LOR did numerically, but not statistically, better than patients who switched for primary failure.CONCLUSIONS: Our data show a superior remission rate in SC to IV anti-TNF switch in UC compared to the IV to SC switch reported in literature.
Original languageEnglish
JournalDigestive and Liver Disease
DOIs
Publication statusPublished - Oct 28 2018

Fingerprint

Ulcerative Colitis
Multicenter Studies
Retrospective Studies
golimumab
Adalimumab
Infliximab
Therapeutics

Cite this

Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab : A multicenter retrospective study. / Viola, Anna; Pugliese, Daniela; Renna, Sara; Furfaro, Federica; Caprioli, Flavio; D'Incà, Renata; Bossa, Fabrizio; Mazza, Stefano; Costantino, Giuseppe; Fantini, Massimo Claudio; Fiorino, Gionata; Alibrandi, Angela; Orlando, Ambrogio; Armuzzi, Alessandro; Fries, Walter.

In: Digestive and Liver Disease, 28.10.2018.

Research output: Contribution to journalArticle

Viola, Anna ; Pugliese, Daniela ; Renna, Sara ; Furfaro, Federica ; Caprioli, Flavio ; D'Incà, Renata ; Bossa, Fabrizio ; Mazza, Stefano ; Costantino, Giuseppe ; Fantini, Massimo Claudio ; Fiorino, Gionata ; Alibrandi, Angela ; Orlando, Ambrogio ; Armuzzi, Alessandro ; Fries, Walter. / Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab : A multicenter retrospective study. In: Digestive and Liver Disease. 2018.
@article{2bdfd44581fd42ada5fbb3471bea69a9,
title = "Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study",
abstract = "BACKGROUND: Anti-TNF therapies infliximab (IFX), adalimumab (ADA), and golimumab (GOL) are approved for treating moderate to severe ulcerative colitis (UC). In UC, only the switch from IFX to ADA has been investigated, reaching no more than 10-43{\%} remission rates at 12 months.AIM: Of the present study was to investigate disease outcome after a switch from subcutaneous (SC) agents to the intravenous (IV) agent (IFX).METHODS: In this retrospective multicentre study, we analysed the charts of UC patients unresponsive/intolerant or with secondary loss of response (LOR) to ADA or GOL who were switched to IFX. We evaluated clinical response and remission together with adverse events at 3, 6, and 12 months follow-up.RESULTS: Seventy-six patients were included; 38 patients started ADA and 38 started GOL for a mean therapy duration of 6 ± 6 months. Indications for switch were adverse events in 3{\%}, primary failure in 79{\%}, and LOR in 18{\%} of patients. Clinical remission was reached by 47{\%}, 50{\%}, and 77{\%} of patients, respectively. Patients that switched for LOR did numerically, but not statistically, better than patients who switched for primary failure.CONCLUSIONS: Our data show a superior remission rate in SC to IV anti-TNF switch in UC compared to the IV to SC switch reported in literature.",
author = "Anna Viola and Daniela Pugliese and Sara Renna and Federica Furfaro and Flavio Caprioli and Renata D'Inc{\`a} and Fabrizio Bossa and Stefano Mazza and Giuseppe Costantino and Fantini, {Massimo Claudio} and Gionata Fiorino and Angela Alibrandi and Ambrogio Orlando and Alessandro Armuzzi and Walter Fries",
note = "Copyright {\circledC} 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.",
year = "2018",
month = "10",
day = "28",
doi = "10.1016/j.dld.2018.10.013",
language = "English",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab

T2 - A multicenter retrospective study

AU - Viola, Anna

AU - Pugliese, Daniela

AU - Renna, Sara

AU - Furfaro, Federica

AU - Caprioli, Flavio

AU - D'Incà, Renata

AU - Bossa, Fabrizio

AU - Mazza, Stefano

AU - Costantino, Giuseppe

AU - Fantini, Massimo Claudio

AU - Fiorino, Gionata

AU - Alibrandi, Angela

AU - Orlando, Ambrogio

AU - Armuzzi, Alessandro

AU - Fries, Walter

N1 - Copyright © 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

PY - 2018/10/28

Y1 - 2018/10/28

N2 - BACKGROUND: Anti-TNF therapies infliximab (IFX), adalimumab (ADA), and golimumab (GOL) are approved for treating moderate to severe ulcerative colitis (UC). In UC, only the switch from IFX to ADA has been investigated, reaching no more than 10-43% remission rates at 12 months.AIM: Of the present study was to investigate disease outcome after a switch from subcutaneous (SC) agents to the intravenous (IV) agent (IFX).METHODS: In this retrospective multicentre study, we analysed the charts of UC patients unresponsive/intolerant or with secondary loss of response (LOR) to ADA or GOL who were switched to IFX. We evaluated clinical response and remission together with adverse events at 3, 6, and 12 months follow-up.RESULTS: Seventy-six patients were included; 38 patients started ADA and 38 started GOL for a mean therapy duration of 6 ± 6 months. Indications for switch were adverse events in 3%, primary failure in 79%, and LOR in 18% of patients. Clinical remission was reached by 47%, 50%, and 77% of patients, respectively. Patients that switched for LOR did numerically, but not statistically, better than patients who switched for primary failure.CONCLUSIONS: Our data show a superior remission rate in SC to IV anti-TNF switch in UC compared to the IV to SC switch reported in literature.

AB - BACKGROUND: Anti-TNF therapies infliximab (IFX), adalimumab (ADA), and golimumab (GOL) are approved for treating moderate to severe ulcerative colitis (UC). In UC, only the switch from IFX to ADA has been investigated, reaching no more than 10-43% remission rates at 12 months.AIM: Of the present study was to investigate disease outcome after a switch from subcutaneous (SC) agents to the intravenous (IV) agent (IFX).METHODS: In this retrospective multicentre study, we analysed the charts of UC patients unresponsive/intolerant or with secondary loss of response (LOR) to ADA or GOL who were switched to IFX. We evaluated clinical response and remission together with adverse events at 3, 6, and 12 months follow-up.RESULTS: Seventy-six patients were included; 38 patients started ADA and 38 started GOL for a mean therapy duration of 6 ± 6 months. Indications for switch were adverse events in 3%, primary failure in 79%, and LOR in 18% of patients. Clinical remission was reached by 47%, 50%, and 77% of patients, respectively. Patients that switched for LOR did numerically, but not statistically, better than patients who switched for primary failure.CONCLUSIONS: Our data show a superior remission rate in SC to IV anti-TNF switch in UC compared to the IV to SC switch reported in literature.

U2 - 10.1016/j.dld.2018.10.013

DO - 10.1016/j.dld.2018.10.013

M3 - Article

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

ER -